1. Scrip
  2. >>New Products

Newron's Parkinson's Disease Drug Xadago Priced At $600-700/Month

 
• By Brenda Sandburg

First new chemical entity for Parkinson's to clear FDA in 10 years, Xadago has a narrower indication than Teva's Azilect and similar pricing.

Neurons and nervous system. 3d render of nerve cells

Newron Pharmaceuticals SPA's Xadago (safinamide) once daily Parkinson's disease drug will launch in the US at a list price ranging from $600-700 for a 30-day supply of the 50 mg or 100 mg tablet. It is on par with Teva Pharmaceutical Industries Ltd.'s competing product Azilect (rasagiline), which has a list price (wholesale acquisition cost) of $694.40 for a 30-day supply.

FDA approved Xadago on March 21 as adjunctive treatment to levodopa/carbidopa in patients experiencing "off" episodes, in which there is an increase in Parkinson's disease symptoms, such as tremor and difficulty walking. It is the first new chemical entity approved for the condition since Azilect's approval in 2006

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from New Products

More from Scrip

Merck KGaA Braces For Volatility But Does Not Expect Europe To Budge On Pricing

 
• By Andrew McConaghie

Shares are hit as German conglomerate lowers revenue forecast.

Leo Roars To A Profit In Q1 As Adbry Grows In US

 
• By Kevin Grogan

The Danish firm's atopic dermatitis drug is holding its own despite strong competition from Sanofi/Regeneron’s Dupixent.

Cipla Leadership’s Early Take On Trump’s Pricing EO And Pipeline Progress

 
• By Anju Ghangurde

Cipla's CEO underlines that US generic prices are already “very significantly comparable” with the rest of the world and expects President Donald Trump's executive order on drug pricing to primarily impact branded pharmaceuticals. The company also shared updates on its US pipeline.